C2

Across TCGA pan-cancer cohorts, C2 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated C2 data layer compared with 26 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in uterine carcinosarcoma (UCS), where higher C2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated C2 expression acts as an unfavorable survival marker.

UCS and COAD are the cancer types where C2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCS	OS	Median	All	0.001	0.690	<.001	36	view →
COAD	OS	Median	All	0.173	0.809	<.001	24	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

C2–UCS (OS)

Open the UCS breakdown →